Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Liabilities (2016 - 2025)

Rocket Pharmaceuticals' Other Non-Current Liabilities history spans 10 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 7.1% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 7.1%, while the annual FY2025 figure was $1.1 million, 7.1% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.1 million at Rocket Pharmaceuticals, roughly flat from $1.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.9 million in Q4 2023 and bottomed at $37000.0 in Q3 2022.
  • The 5-year median for Other Non-Current Liabilities is $1.1 million (2024), against an average of $1.1 million.
  • The largest annual shift saw Other Non-Current Liabilities surged 4951.35% in 2023 before it crashed 61.14% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $80000.0 in 2021, then skyrocketed by 3143.75% to $2.6 million in 2022, then grew by 13.14% to $2.9 million in 2023, then plummeted by 61.14% to $1.1 million in 2024, then decreased by 7.1% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Other Non-Current Liabilities are $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025).